Responsive Dual-Targeting Exosome as a Drug Carrier for Combination Cancer Immunotherapy
Open Access
- 1 January 2021
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Research
Abstract
Recently, combination immunotherapy, which incorporates the activation of the immune system and inhibition of immune escape, has been proved to be a new powerful strategy for more efficient tumor suppression compared to monotherapy. However, the major challenge is how to integrate multiple immune drugs together and efficiently convey these drugs to tumor sites. Although a variety of nanomaterials have been exploited as carriers for targeting tumor issues and the delivery of multiple drugs, their potential toxicity, immune rejection, and stability are still controversial for clinical application. Here, we proposed endogenic exosomes as drug carriers to deliver two antibodies acting as tumor-targeting molecules and block checkpoint inhibitors with specific response to the tumor microenvironment and costimulatory molecules for further improvement of therapeutic effect. The versatile exosomes exhibit excellent biocompatibility and provide a combination immunotherapy platform with synergistic advantages of activation of immune response and inhibition of immune escape.Keywords
Funding Information
- Local Science and Technology Development Fund guided by the Central Government (YDZX20203700002568)
- Taishan Scholar Project of Shandong Province (tsqn.201909077)
- Natural Science Foundation of Shandong Province (ZR2019JQ06)
- National Natural Science Foundation of China (21804082, 91859111, 21927811)
This publication has 36 references indexed in Scilit:
- Transformation of Cell‐Derived Microparticles into Quantum‐Dot‐Labeled Nanovectors for Antitumor siRNA DeliveryAngewandte Chemie, 2014
- IL-2: The First Effective Immunotherapy for Human CancerThe Journal of Immunology, 2014
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Combining immunotherapy and targeted therapies in cancer treatmentNature Reviews Cancer, 2012
- Cancer immunotherapy comes of ageNature, 2011
- Impact of Nanotechnology on Drug DeliveryACS Nano, 2009
- Nanoparticles: pharmacological and toxicological significanceBritish Journal of Pharmacology, 2007
- Inflammation and cancer: back to Virchow?The Lancet, 2001